Progressive grey matter atrophy in clinically early relapsing-remitting multiple sclerosis
Brain atrophy appears to occur in patients with multiple sclerosis (MS) in excess of that associated with normal ageing, and may be observed early in the clinical course of the disease. The dynamics and tissue specificity of this process remain unclear. This preliminary study explored the evolution...
Gespeichert in:
| Veröffentlicht in: | Multiple sclerosis 2004-08, Vol.10 (4), p.387-391 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 391 |
|---|---|
| container_issue | 4 |
| container_start_page | 387 |
| container_title | Multiple sclerosis |
| container_volume | 10 |
| creator | Chard, D T Griffin, C M Rashid, W Davies, G R Altmann, D R Kapoor, R Barker, G J Thompson, A J Miller, D H |
| description | Brain atrophy appears to occur in patients with multiple sclerosis (MS) in excess of that associated with normal ageing, and may be observed early in the clinical course of the disease. The dynamics and tissue specificity of this process remain unclear. This preliminary study explored the evolution of brain grey matter (GM) and white matter (WM) volume loss (as fractions of total intracranial volumes) in 13 subjects with relapsing-remitting MS (mean disease duration 1.9 years at first scan), compared with nine normal control (NC) subjects. Subjects were scanned every six months for 18 months. In MS compared with NC subjects, significant differences in WM fractional volumes were observed at baseline (mean-5.8%, P/0.008) but no apparent progressive WM tissue loss was detected. In contrast, while no significant differences in GM fractional volumes were observed at baseline, there was significantly greater time-related volume loss in MS compared with NC subjects over the follow-up period (circa-0.0086 per year in MS subjects,-0.0021 per year in the NC subjects, difference 0.010). These results suggest that while both GM and WM atrophy are seen early in the clinical course of MS, they may not occur concurrently and may evolve at different rates. |
| doi_str_mv | 10.1191/1352458504ms1050oa |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_66812402</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1191_1352458504ms1050oa</sage_id><sourcerecordid>800194891</sourcerecordid><originalsourceid>FETCH-LOGICAL-c396t-2b3d2aebf089b0c035f71922e329a227fc2d7e0c02e51bdd0bc687c8334f18dd3</originalsourceid><addsrcrecordid>eNp9kEtLxDAQx4Movr-ABymC3qqTpN2kR1l8gaAHvXgpaTpdI-nDTCvstzeyC4qCl5k_zG9ef8aOOJxzXvALLnOR5TqHrCUOOfRmg-3yTKkUCgWbUUcg_SJ22B7RGwAoJfNttsNzKRTIbJe9PIZ-EZDIfWASxTJpzThiSMwY-uF1mbgusd51zhrvlwmaEGNAbwZy3SIN2LpxjCppJz-6wWNC1mPoydEB22qMJzxc5332fH31NL9N7x9u7uaX96mVxWxMRSVrYbBqQBcVWJB5o3ghBEpRGCFUY0WtMBYE5ryqa6jsTCurpcwaruta7rOz1dwh9O8T0li2jix6bzrsJypnM81FBiKCJ7_At34KXbytFFxrWcS1ERIryMYnKGBTDsG1JixLDuWX7eVf22PT8XryVLVYf7esfY7A6RowFJ1sgumsox9coQE0RO5ixZFZ4Pd5_6z-BOJvmuY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>218839192</pqid></control><display><type>article</type><title>Progressive grey matter atrophy in clinically early relapsing-remitting multiple sclerosis</title><source>Access via SAGE</source><source>MEDLINE</source><creator>Chard, D T ; Griffin, C M ; Rashid, W ; Davies, G R ; Altmann, D R ; Kapoor, R ; Barker, G J ; Thompson, A J ; Miller, D H</creator><creatorcontrib>Chard, D T ; Griffin, C M ; Rashid, W ; Davies, G R ; Altmann, D R ; Kapoor, R ; Barker, G J ; Thompson, A J ; Miller, D H</creatorcontrib><description>Brain atrophy appears to occur in patients with multiple sclerosis (MS) in excess of that associated with normal ageing, and may be observed early in the clinical course of the disease. The dynamics and tissue specificity of this process remain unclear. This preliminary study explored the evolution of brain grey matter (GM) and white matter (WM) volume loss (as fractions of total intracranial volumes) in 13 subjects with relapsing-remitting MS (mean disease duration 1.9 years at first scan), compared with nine normal control (NC) subjects. Subjects were scanned every six months for 18 months. In MS compared with NC subjects, significant differences in WM fractional volumes were observed at baseline (mean-5.8%, P/0.008) but no apparent progressive WM tissue loss was detected. In contrast, while no significant differences in GM fractional volumes were observed at baseline, there was significantly greater time-related volume loss in MS compared with NC subjects over the follow-up period (circa-0.0086 per year in MS subjects,-0.0021 per year in the NC subjects, difference 0.010). These results suggest that while both GM and WM atrophy are seen early in the clinical course of MS, they may not occur concurrently and may evolve at different rates.</description><identifier>ISSN: 1352-4585</identifier><identifier>EISSN: 1477-0970</identifier><identifier>DOI: 10.1191/1352458504ms1050oa</identifier><identifier>PMID: 15327034</identifier><identifier>CODEN: MUSCFZ</identifier><language>eng</language><publisher>Thousand Oaks, CA: SAGE Publications</publisher><subject>Adult ; Atrophy ; Biological and medical sciences ; Brain - pathology ; Case-Control Studies ; Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases ; Disability Evaluation ; Disease Progression ; Echo-Planar Imaging ; Female ; Humans ; Immunomodulators ; Longitudinal Studies ; Male ; Medical sciences ; Middle Aged ; Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis ; Multiple Sclerosis, Relapsing-Remitting - diagnosis ; Multiple Sclerosis, Relapsing-Remitting - physiopathology ; Neurology ; Periaqueductal Gray - pathology ; Pharmacology. Drug treatments</subject><ispartof>Multiple sclerosis, 2004-08, Vol.10 (4), p.387-391</ispartof><rights>2004 INIST-CNRS</rights><rights>2004 Arnold</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c396t-2b3d2aebf089b0c035f71922e329a227fc2d7e0c02e51bdd0bc687c8334f18dd3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.1191/1352458504ms1050oa$$EPDF$$P50$$Gsage$$H</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.1191/1352458504ms1050oa$$EHTML$$P50$$Gsage$$H</linktohtml><link.rule.ids>314,780,784,21819,27924,27925,43621,43622</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=15980080$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15327034$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chard, D T</creatorcontrib><creatorcontrib>Griffin, C M</creatorcontrib><creatorcontrib>Rashid, W</creatorcontrib><creatorcontrib>Davies, G R</creatorcontrib><creatorcontrib>Altmann, D R</creatorcontrib><creatorcontrib>Kapoor, R</creatorcontrib><creatorcontrib>Barker, G J</creatorcontrib><creatorcontrib>Thompson, A J</creatorcontrib><creatorcontrib>Miller, D H</creatorcontrib><title>Progressive grey matter atrophy in clinically early relapsing-remitting multiple sclerosis</title><title>Multiple sclerosis</title><addtitle>Mult Scler</addtitle><description>Brain atrophy appears to occur in patients with multiple sclerosis (MS) in excess of that associated with normal ageing, and may be observed early in the clinical course of the disease. The dynamics and tissue specificity of this process remain unclear. This preliminary study explored the evolution of brain grey matter (GM) and white matter (WM) volume loss (as fractions of total intracranial volumes) in 13 subjects with relapsing-remitting MS (mean disease duration 1.9 years at first scan), compared with nine normal control (NC) subjects. Subjects were scanned every six months for 18 months. In MS compared with NC subjects, significant differences in WM fractional volumes were observed at baseline (mean-5.8%, P/0.008) but no apparent progressive WM tissue loss was detected. In contrast, while no significant differences in GM fractional volumes were observed at baseline, there was significantly greater time-related volume loss in MS compared with NC subjects over the follow-up period (circa-0.0086 per year in MS subjects,-0.0021 per year in the NC subjects, difference 0.010). These results suggest that while both GM and WM atrophy are seen early in the clinical course of MS, they may not occur concurrently and may evolve at different rates.</description><subject>Adult</subject><subject>Atrophy</subject><subject>Biological and medical sciences</subject><subject>Brain - pathology</subject><subject>Case-Control Studies</subject><subject>Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases</subject><subject>Disability Evaluation</subject><subject>Disease Progression</subject><subject>Echo-Planar Imaging</subject><subject>Female</subject><subject>Humans</subject><subject>Immunomodulators</subject><subject>Longitudinal Studies</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis</subject><subject>Multiple Sclerosis, Relapsing-Remitting - diagnosis</subject><subject>Multiple Sclerosis, Relapsing-Remitting - physiopathology</subject><subject>Neurology</subject><subject>Periaqueductal Gray - pathology</subject><subject>Pharmacology. Drug treatments</subject><issn>1352-4585</issn><issn>1477-0970</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp9kEtLxDAQx4Movr-ABymC3qqTpN2kR1l8gaAHvXgpaTpdI-nDTCvstzeyC4qCl5k_zG9ef8aOOJxzXvALLnOR5TqHrCUOOfRmg-3yTKkUCgWbUUcg_SJ22B7RGwAoJfNttsNzKRTIbJe9PIZ-EZDIfWASxTJpzThiSMwY-uF1mbgusd51zhrvlwmaEGNAbwZy3SIN2LpxjCppJz-6wWNC1mPoydEB22qMJzxc5332fH31NL9N7x9u7uaX96mVxWxMRSVrYbBqQBcVWJB5o3ghBEpRGCFUY0WtMBYE5ryqa6jsTCurpcwaruta7rOz1dwh9O8T0li2jix6bzrsJypnM81FBiKCJ7_At34KXbytFFxrWcS1ERIryMYnKGBTDsG1JixLDuWX7eVf22PT8XryVLVYf7esfY7A6RowFJ1sgumsox9coQE0RO5ixZFZ4Pd5_6z-BOJvmuY</recordid><startdate>200408</startdate><enddate>200408</enddate><creator>Chard, D T</creator><creator>Griffin, C M</creator><creator>Rashid, W</creator><creator>Davies, G R</creator><creator>Altmann, D R</creator><creator>Kapoor, R</creator><creator>Barker, G J</creator><creator>Thompson, A J</creator><creator>Miller, D H</creator><general>SAGE Publications</general><general>Arnold</general><general>Sage Publications Ltd</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7TK</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9-</scope><scope>K9.</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>200408</creationdate><title>Progressive grey matter atrophy in clinically early relapsing-remitting multiple sclerosis</title><author>Chard, D T ; Griffin, C M ; Rashid, W ; Davies, G R ; Altmann, D R ; Kapoor, R ; Barker, G J ; Thompson, A J ; Miller, D H</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c396t-2b3d2aebf089b0c035f71922e329a227fc2d7e0c02e51bdd0bc687c8334f18dd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Adult</topic><topic>Atrophy</topic><topic>Biological and medical sciences</topic><topic>Brain - pathology</topic><topic>Case-Control Studies</topic><topic>Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases</topic><topic>Disability Evaluation</topic><topic>Disease Progression</topic><topic>Echo-Planar Imaging</topic><topic>Female</topic><topic>Humans</topic><topic>Immunomodulators</topic><topic>Longitudinal Studies</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis</topic><topic>Multiple Sclerosis, Relapsing-Remitting - diagnosis</topic><topic>Multiple Sclerosis, Relapsing-Remitting - physiopathology</topic><topic>Neurology</topic><topic>Periaqueductal Gray - pathology</topic><topic>Pharmacology. Drug treatments</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chard, D T</creatorcontrib><creatorcontrib>Griffin, C M</creatorcontrib><creatorcontrib>Rashid, W</creatorcontrib><creatorcontrib>Davies, G R</creatorcontrib><creatorcontrib>Altmann, D R</creatorcontrib><creatorcontrib>Kapoor, R</creatorcontrib><creatorcontrib>Barker, G J</creatorcontrib><creatorcontrib>Thompson, A J</creatorcontrib><creatorcontrib>Miller, D H</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Multiple sclerosis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chard, D T</au><au>Griffin, C M</au><au>Rashid, W</au><au>Davies, G R</au><au>Altmann, D R</au><au>Kapoor, R</au><au>Barker, G J</au><au>Thompson, A J</au><au>Miller, D H</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Progressive grey matter atrophy in clinically early relapsing-remitting multiple sclerosis</atitle><jtitle>Multiple sclerosis</jtitle><addtitle>Mult Scler</addtitle><date>2004-08</date><risdate>2004</risdate><volume>10</volume><issue>4</issue><spage>387</spage><epage>391</epage><pages>387-391</pages><issn>1352-4585</issn><eissn>1477-0970</eissn><coden>MUSCFZ</coden><abstract>Brain atrophy appears to occur in patients with multiple sclerosis (MS) in excess of that associated with normal ageing, and may be observed early in the clinical course of the disease. The dynamics and tissue specificity of this process remain unclear. This preliminary study explored the evolution of brain grey matter (GM) and white matter (WM) volume loss (as fractions of total intracranial volumes) in 13 subjects with relapsing-remitting MS (mean disease duration 1.9 years at first scan), compared with nine normal control (NC) subjects. Subjects were scanned every six months for 18 months. In MS compared with NC subjects, significant differences in WM fractional volumes were observed at baseline (mean-5.8%, P/0.008) but no apparent progressive WM tissue loss was detected. In contrast, while no significant differences in GM fractional volumes were observed at baseline, there was significantly greater time-related volume loss in MS compared with NC subjects over the follow-up period (circa-0.0086 per year in MS subjects,-0.0021 per year in the NC subjects, difference 0.010). These results suggest that while both GM and WM atrophy are seen early in the clinical course of MS, they may not occur concurrently and may evolve at different rates.</abstract><cop>Thousand Oaks, CA</cop><pub>SAGE Publications</pub><pmid>15327034</pmid><doi>10.1191/1352458504ms1050oa</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1352-4585 |
| ispartof | Multiple sclerosis, 2004-08, Vol.10 (4), p.387-391 |
| issn | 1352-4585 1477-0970 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_66812402 |
| source | Access via SAGE; MEDLINE |
| subjects | Adult Atrophy Biological and medical sciences Brain - pathology Case-Control Studies Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases Disability Evaluation Disease Progression Echo-Planar Imaging Female Humans Immunomodulators Longitudinal Studies Male Medical sciences Middle Aged Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis Multiple Sclerosis, Relapsing-Remitting - diagnosis Multiple Sclerosis, Relapsing-Remitting - physiopathology Neurology Periaqueductal Gray - pathology Pharmacology. Drug treatments |
| title | Progressive grey matter atrophy in clinically early relapsing-remitting multiple sclerosis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T11%3A14%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Progressive%20grey%20matter%20atrophy%20in%20clinically%20early%20relapsing-remitting%20multiple%20sclerosis&rft.jtitle=Multiple%20sclerosis&rft.au=Chard,%20D%20T&rft.date=2004-08&rft.volume=10&rft.issue=4&rft.spage=387&rft.epage=391&rft.pages=387-391&rft.issn=1352-4585&rft.eissn=1477-0970&rft.coden=MUSCFZ&rft_id=info:doi/10.1191/1352458504ms1050oa&rft_dat=%3Cproquest_cross%3E800194891%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=218839192&rft_id=info:pmid/15327034&rft_sage_id=10.1191_1352458504ms1050oa&rfr_iscdi=true |